Chronic obstructive pulmonary disease
Conditions
Interventions
Stable COPD subjects:None
AECOPD subjects:None
Sponsors
Zhujiang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Stable COPD subjects: (1) age = 40 years; (2) persistent respiratory symptoms, including recurrent cough, sputum and progressive dyspnea, with no significant aggravation of the above symptoms in the past 14 days; (3) the presence of irreversible airflow limitation (FEV1/FVC <70% after the inhalation of bronchodilators), with an improvement in the rate of FEV1 <12% and the improvement in the amount of FEV1 <200 ml. AECOPD subjects: (1) age = 40 years; (2) persistent respiratory symptoms, including recurrent cough, sputum and progressive dyspnea, in the past 14 days the above symptoms suddenly worsened, exceeding the range of daily variability, and self-adjustment of drugs can not be improved; (3) the existence of irreversible airflow limitation (after inhalation of bronchodilators, FEV1/FVC <70%), the rate of improvement of FEV1 <12% and the amount of improvement <200ml. FEV1/FVC <70% after inhalation of bronchodilators, FEV1 improvement rate <12% and improvement volume <200ml.
Exclusion criteria
Exclusion criteria: Stable COPD subjects: ? Combined with other lung diseases affecting respiratory symptoms and lung structure, such as bronchiectasis, diffuse panuveitis, pneumonia, active tuberculosis, lung cancer, pulmonary atelectasis, post-pneumonectomy, pulmonary embolism, interstitial lung disease, etc.; ? Combined with pleural and thoracic diseases, such as large amount of pleural effusion, pneumothorax, obvious occupation of the pleura, and thoracic deformities; ? Combined with extrapulmonary diseases affecting respiratory symptoms, such as cardiogenic pulmonary edema, severe anemia, malaise, etc.; ? Combined with incomplete clinical data of lung function, etc. symptoms of extrapulmonary diseases, such as cardiogenic pulmonary edema, severe anemia, malignant fluid, etc.; ? incomplete clinical data such as lung function. AECOPD subjects: ? Combined with other lung diseases affecting respiratory symptoms and lung structure, such as bronchiectasis, diffuse panbronchiolitis, pneumonia, active tuberculosis, lung cancer, pulmonary atelectasis, post-pneumonectomy, pulmonary embolism, interstitial lung disease, etc.; (2) Combined with pleural and thoracic diseases, such as large amount of pleural effusion, pneumothorax, obvious occupation of the pleura, and thoracic deformities; (3) Combined with extrapulmonary diseases affecting respiratory symptoms, such as cardiogenic pulmonary edema, severe anemia, malaise, etc.; (4) incomplete clinical data on pulmonary function. (iii) Combination of extrapulmonary diseases affecting respiratory symptoms, such as cardiogenic pulmonary edema, severe anemia, malignant fluid, etc.; (iv) Incomplete clinical data on pulmonary function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Forced Expiratory Volume in one second; | — |
Countries
China
Contacts
Public ContactChen Xin
Zhujiang Hospital, Southern Medical University
Outcome results
None listed